ClinicalTrials.gg

Program

zilucoplan

Also written as “Zilucoplan”, “zilucoplan (RA101495)” and “Zilucoplan (RA101495)”.

Its studies are mostly in Myasthenia Gravis · Hemoglobinuria, Paroxysmal · Muscular Diseases · COVID-19, led by 2 companies.

Furthest: phase 3, since Oct 2, 201914 company-led studies, 3 open or runningNext primary completion: Mar 23, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCB133 open or runningphase 3since Oct 2, 2019Jan 20, 2017Mar 23, 2027phase 1 · NCT06961747
Amgen10 open or runningphase 3since Oct 14, 2020Oct 14, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 20, 2017First study: phase 2 study in Hemoglobinuria, ParoxysmalNew to UCBUCB · NCT03030183 · 3 enrolled · United States
  2. Mar 8, 2017Phase 2 study in Hemoglobinuria, ParoxysmalUCB · NCT03078582 · 26 enrolled · Australia, Canada, Denmark and more
  3. Jul 17, 2017Phase 2 study in Hemoglobinuria, ParoxysmalUCB · NCT03225287 · 19 enrolled · United States, Australia, Canada and more
  4. Oct 16, 2017Phase 2 study in Myasthenia GravisUCB · NCT03315130 · 45 enrolled · United States, Canada
  5. Jul 17, 2019Phase 2 study in Immune Mediated Necrotizing MyopathyUCB · NCT04025632 · 27 enrolled · United States, France, Netherlands and more
  6. Oct 2, 20192 phase 3 studies in Myasthenia GravisUCB · NCT04225871, NCT04115293
  7. Oct 14, 2020Amgen's first study: phase 3 study in COVID-19New to AmgenAmgen · NCT04590586 · 515 enrolled · United States, Argentina, Brazil and more
  8. Aug 22, 2022Phase 3 study in Myasthenia GravisUCB · NCT05514873 · 26 enrolled · United States
  9. Sep 20, 2023Phase 3 study in Myasthenia GravisUCB · NCT06055959 · 8 planned · United States, Italy, Poland and more
  10. May 23, 2024Phase 3 study in Myasthenia GravisUCB · NCT06435312 · 8 planned · Italy, Poland, South Korea and more
  11. Jun 18, 2024Phase 3 study in Myasthenia GravisUCB · NCT06471361 · 31 enrolled · United States, Poland, United Kingdom
  12. Jul 15, 2024Phase 1 study in Healthy VolunteersUCB · NCT06511076 · 14 enrolled · Netherlands
  13. Apr 29, 2025Phase 1 study in Healthy ParticipantsUCB · NCT06961747 · 15 planned · United States
  14. Nov 5, 2026Primary completion moved from 2026-11-16 to 2027-05-12Date moved laterphase 3 · +6 months · NCT06055959

Ahead

  1. Mar 23, 2027Primary completion: phase 1 study in Healthy ParticipantsUCB · NCT06961747
  2. May 12, 2027Primary completion: phase 3 study in Myasthenia GravisUCB · NCT06055959
  3. Oct 26, 2027Primary completion: phase 3 study in Myasthenia GravisUCB · NCT06435312

TargetBeta

C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
ravulizumabruleAstraZenecaphase 435
pozelimabruleRegeneron Pharmaceuticalsphase 414
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
cemdisiranruleRegeneron Pharmaceuticalsphase 310
ABBV-6628AbbViephase 21

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06961747Healthy Participants · United States1RecruitingUCBMar 23, 202715
NCT06511076Healthy Volunteers · Netherlands1CompletedUCBNov 26, 202414
NCT06471361Myasthenia Gravis · United States, Poland, United Kingdom3CompletedUCBJan 28, 202531
NCT06435312Myasthenia Gravis · Italy, Poland, South Korea and more3By invitationUCBOct 26, 20278
NCT06055959Myasthenia Gravis · United States, Italy, Poland and more3RecruitingUCBMay 12, 20278
NCT05514873Myasthenia Gravis · United States3CompletedUCBMar 13, 202426
NCT04590586COVID-19 · United States, Argentina, Brazil and more3CompletedAmgenAug 3, 2021515
NCT04225871Myasthenia Gravis · United States, Canada, France and more3CompletedUCBJul 31, 2026200
NCT04115293Myasthenia Gravis · United States, Canada, France and more3CompletedUCBDec 30, 2021174
NCT04025632Immune Mediated Necrotizing Myopathy · United States, France, Netherlands and more2TerminatedUCBMar 4, 202127
NCT03315130Myasthenia Gravis · United States, Canada2CompletedUCBDec 10, 201845
NCT03225287Hemoglobinuria, Paroxysmal · United States, Australia, Canada and more2TerminatedUCBSep 7, 202119
NCT03078582Hemoglobinuria, Paroxysmal · Australia, Canada, Denmark and more2CompletedUCBMar 28, 201826
NCT03030183Hemoglobinuria, Paroxysmal · United States2CompletedUCBMar 28, 20183

How it is read

Names in the registry

  • “Zilucoplan”, 6 entries
  • “zilucoplan (RA101495)”, 4 entries
  • “Zilucoplan (RA101495)”, 3 entries
  • “zilucoplan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.